Posted On: 12/15/2014 12:42:14 PM
Post# of 102854
$ACT Company News
What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Actavis to buy Allergan in $66 billion deal 9:35 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Actavis confirms to buy Allergan in $66 billion deal 9:30 a.m. Nov. 17, 2014 - Ciara Linnane
Actavis, Allergan close to a deal 8:33 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Allergan, Actavis near cash-and-stock deal: WSJ 1:48 p.m. Nov. 16, 2014 - Andria Cheng
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn
Ackman urges Allergan to open sale process, negotiate 10:33 a.m. Nov. 7, 2014 - Chelsey Dulaney
Actavis sales surge, exceed forecasts 7:51 a.m. Nov. 5, 2014 - MarketWatch.com
Media, consumer-based company earnings to test stock rally 4:30 a.m. Nov. 2, 2014 - Wallace Witkowski
Pfizer sales fall less than expected 7:34 a.m. Oct. 28, 2014 - MarketWatch.com
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan
Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015 9:27 a.m. Today - TheStreet.com
5 “Best of the Best” Stocks for 2015 5:11 a.m. Today - InvestorPlace.com
What Investors Can Learn From The Portfolios Of Fund Managers 5:47 a.m. Dec. 14, 2014 - Seeking Alpha
Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog 3:20 p.m. Dec. 12, 2014 - Zacks.com
Judge orders Actavis to keep selling Alzheimer's drug 12:49 p.m. Dec. 12, 2014 - Seeking Alpha
bluebird bio (BLUE) Soars on Data from LentiGlobin Study - Analyst Blog 4:45 p.m. Dec. 11, 2014 - Zacks.com
Mylan Among First to Launch Generic Celebrex - Analyst Blog 4:22 p.m. Dec. 11, 2014 - Zacks.com
Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog 3:20 p.m. Dec. 11, 2014 - Zacks.com
Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa - Analyst Blog 3:30 p.m. Dec. 10, 2014 - Zacks.com
Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog 2:50 p.m. Dec. 10, 2014 - Zacks.com
What a Generic Celebrex Means for Pfizer and for Actavis 9:57 a.m. Dec. 10, 2014 - 247WallSt.com
The Gurus to Follow Based on Sector - Part 2 3:20 p.m. Dec. 9, 2014 - GuruFocus.com
Merck to Buy Cubist for $8.4 Billion 9:46 p.m. Dec. 8, 2014 - The Wall Street Journal Interactive Edition
Google, Microsoft Dominate Mutual Funds, Apple Still Most Popular In Hedge Funds: Citigroup 8:13 p.m. Dec. 8, 2014 - Seeking Alpha
Actavis' Antibiotic Backed for FDA Approval, Response in Q1 - Analyst Blog 6:30 p.m. Dec. 8, 2014 - Zacks.com
Top Global Stocks: Jazz, Actavis In IBD's World List 5:39 p.m. Dec. 8, 2014 - Investors Business Daily
Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data - Analyst Blog 5:10 p.m. Dec. 8, 2014 - Zacks.com
Merck Acquiring Cubist, Focusing On Hospital Care 10:48 a.m. Dec. 8, 2014 - Investors Business Daily
Deals, Deals, Deals: What Made 2014 Such a Big Year for Mergers 6:10 a.m. Dec. 8, 2014 - TheStreet.com
Big Number: Deals Fuel Bond Boom 9:44 p.m. Dec. 7, 2014 - The Wall Street Journal Interactive Edition
Actavis Launches Generic Version of Celebrex® 9:28 a.m. Dec. 10, 2014 - PR Newswire - PRF
Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 4:46 p.m. Dec. 5, 2014 - PR Newswire - PRF
No Wrinkles in Actavis' $66 Billion Deal to Buy Botox Maker Allergan, an Industrial Info News Alert 6:15 a.m. Dec. 3, 2014 - Marketwired
Stock Updates on Pharma Services - Avanir Pharma, Zoetis, Allergan, Mallinckrodt, and Actavis 8:30 a.m. Nov. 25, 2014 - PR Newswire - PRF
Critical Alerts For Gold Fields, Actavis, Trina Solar Limited, Alcoa and Herbalife Released By InvestorsObserver 9:31 a.m. Nov. 19, 2014 - PR Newswire - PRF
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 10:32 a.m. Nov. 17, 2014 - PR Newswire - PRF
Valeant Comments On Allergan Announcement 9:29 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue 9:15 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer 8:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients 8:00 a.m. Nov. 13, 2014 - PR Newswire - PRF
Actavis Names Maria Teresa Hilado Chief Financial Officer 4:15 p.m. Nov. 10, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 6:45 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 6:30 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 4:15 p.m. Oct. 31, 2014 - PR Newswire - PRF
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt 8:40 a.m. Oct. 20, 2014 - PR Newswire - PRF
What a week: Botox haze, merger Monday and The Tanned One 9:19 a.m. Nov. 21, 2014 - Marek Fuchs
Valeant's stock rises after new $2 billion buyback plan announced 12:00 p.m. Nov. 20, 2014 - Tomi Kilgore
La-Z-Boy shares rally after earnings beat targets 4:41 p.m. Nov. 18, 2014 - Sue Chang
S&P, Dow ring up records Tuesday 4:35 p.m. Nov. 18, 2014 - Barbara Kollmeyer
Actavis shares outpace buyout target’s gains 12:30 p.m. Nov. 18, 2014 - Russ Britt
S&P 500 registers 42nd record close in skittish market 4:59 p.m. Nov. 17, 2014 - Carla Mozee
Urban Outfitters slides after earnings miss expectations 4:43 p.m. Nov. 17, 2014 - Sue Chang
Valeant says it won’t meet Actavis’s offer 12:18 p.m. Nov. 17, 2014 - Russ Britt
If you're looking big pharma, look no further than Actavis 11:33 a.m. Nov. 17, 2014 - The Trading Deck
Actavis to buy Allergan in $66 billion deal 9:35 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Actavis confirms to buy Allergan in $66 billion deal 9:30 a.m. Nov. 17, 2014 - Ciara Linnane
Actavis, Allergan close to a deal 8:33 a.m. Nov. 17, 2014 - Jonathan D. Rockoff
Allergan, Actavis near cash-and-stock deal: WSJ 1:48 p.m. Nov. 16, 2014 - Andria Cheng
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Nov. 11, 2014 - Philip van Doorn
Ackman urges Allergan to open sale process, negotiate 10:33 a.m. Nov. 7, 2014 - Chelsey Dulaney
Actavis sales surge, exceed forecasts 7:51 a.m. Nov. 5, 2014 - MarketWatch.com
Media, consumer-based company earnings to test stock rally 4:30 a.m. Nov. 2, 2014 - Wallace Witkowski
Pfizer sales fall less than expected 7:34 a.m. Oct. 28, 2014 - MarketWatch.com
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan
Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015 9:27 a.m. Today - TheStreet.com
5 “Best of the Best” Stocks for 2015 5:11 a.m. Today - InvestorPlace.com
What Investors Can Learn From The Portfolios Of Fund Managers 5:47 a.m. Dec. 14, 2014 - Seeking Alpha
Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog 3:20 p.m. Dec. 12, 2014 - Zacks.com
Judge orders Actavis to keep selling Alzheimer's drug 12:49 p.m. Dec. 12, 2014 - Seeking Alpha
bluebird bio (BLUE) Soars on Data from LentiGlobin Study - Analyst Blog 4:45 p.m. Dec. 11, 2014 - Zacks.com
Mylan Among First to Launch Generic Celebrex - Analyst Blog 4:22 p.m. Dec. 11, 2014 - Zacks.com
Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog 3:20 p.m. Dec. 11, 2014 - Zacks.com
Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa - Analyst Blog 3:30 p.m. Dec. 10, 2014 - Zacks.com
Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog 2:50 p.m. Dec. 10, 2014 - Zacks.com
What a Generic Celebrex Means for Pfizer and for Actavis 9:57 a.m. Dec. 10, 2014 - 247WallSt.com
The Gurus to Follow Based on Sector - Part 2 3:20 p.m. Dec. 9, 2014 - GuruFocus.com
Merck to Buy Cubist for $8.4 Billion 9:46 p.m. Dec. 8, 2014 - The Wall Street Journal Interactive Edition
Google, Microsoft Dominate Mutual Funds, Apple Still Most Popular In Hedge Funds: Citigroup 8:13 p.m. Dec. 8, 2014 - Seeking Alpha
Actavis' Antibiotic Backed for FDA Approval, Response in Q1 - Analyst Blog 6:30 p.m. Dec. 8, 2014 - Zacks.com
Top Global Stocks: Jazz, Actavis In IBD's World List 5:39 p.m. Dec. 8, 2014 - Investors Business Daily
Bristol-Myers Posts Positive Opdivo Hodgkin Lymphoma Data - Analyst Blog 5:10 p.m. Dec. 8, 2014 - Zacks.com
Merck Acquiring Cubist, Focusing On Hospital Care 10:48 a.m. Dec. 8, 2014 - Investors Business Daily
Deals, Deals, Deals: What Made 2014 Such a Big Year for Mergers 6:10 a.m. Dec. 8, 2014 - TheStreet.com
Big Number: Deals Fuel Bond Boom 9:44 p.m. Dec. 7, 2014 - The Wall Street Journal Interactive Edition
Actavis Launches Generic Version of Celebrex® 9:28 a.m. Dec. 10, 2014 - PR Newswire - PRF
Anti-Infective Advisory Committee Recommends Approval Of Actavis' Ceftazidime-Avibactam 4:46 p.m. Dec. 5, 2014 - PR Newswire - PRF
No Wrinkles in Actavis' $66 Billion Deal to Buy Botox Maker Allergan, an Industrial Info News Alert 6:15 a.m. Dec. 3, 2014 - Marketwired
Stock Updates on Pharma Services - Avanir Pharma, Zoetis, Allergan, Mallinckrodt, and Actavis 8:30 a.m. Nov. 25, 2014 - PR Newswire - PRF
Critical Alerts For Gold Fields, Actavis, Trina Solar Limited, Alcoa and Herbalife Released By InvestorsObserver 9:31 a.m. Nov. 19, 2014 - PR Newswire - PRF
ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 10:32 a.m. Nov. 17, 2014 - PR Newswire - PRF
Valeant Comments On Allergan Announcement 9:29 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue 9:15 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer 8:00 a.m. Nov. 17, 2014 - PR Newswire - PRF
Actavis Announces FDA Acceptance of sNDA for SAPHRIS® (asenapine) for the Treatment of Bipolar I Disorder in Pediatric Patients 8:00 a.m. Nov. 13, 2014 - PR Newswire - PRF
Actavis Names Maria Teresa Hilado Chief Financial Officer 4:15 p.m. Nov. 10, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 6:45 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 6:30 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 4:15 p.m. Oct. 31, 2014 - PR Newswire - PRF
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt 8:40 a.m. Oct. 20, 2014 - PR Newswire - PRF
(0)
(0)
